- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01771783
RAS-Peptide-Profile Study in Healthy Male Subjects (RAS)
Single-center, Randomized, Open-label, 3-way Crossover Study to Characterize the RAS-peptide-profile After Single and Repeated Oral Administration of Different RAS-inhibitors in Healthy Male Subjects
The primary objective is the characterization of the RAS peptide profiles after single and repeated oral administration of a renin inhibitor, an ACE inhibitor and an angiotensin receptor blocker in healthy volunteers.
Secondary objectives are the correlation of RAS peptide profiles with pharmacokinetic profiles of the different RAS inhibitors and with pharmacodynamic parameters such as blood pressure and heart rate. Output of the classic RAS system will be assessed using aldosterone concentrations. Fluid and sodium intake will be monitored using sodium concentration and total volume in 24h urine.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
-
Basel, Sveits, 4031
- Department Clinical Pharmacology, University Hospital Basel
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Male aged between 18 and 45 years (inclusive) at screening.
- Body mass index (BMI) between 18 and 28 kg/m2 (inclusive) and body weight at least 50 kg at screening.
- Systolic blood pressure (SBP) 100-140 mmHg, diastolic blood pressure (DBP) 60-90 mmHg and heart rate (HR) 45-90 bpm (inclusive), measured on the leading arm*, after 5 min in the supine position at screening.
- Signed informed consent prior to any study-mandated procedure.
- No clinically significant findings on the physical examination at screening.
- 12-lead electrocardiogram (ECG) without clinically relevant abnormalities at screening.
- Hematology and clinical chemistry results not deviating from the normal range to a clinically relevant extent at screening.
Ability to communicate well with the investigator and to understand and comply with the requirements of the study.
- leading arm right = writing with right hand
Exclusion Criteria:
- Smoking > 5 cigarettes per day
- History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening.
- Loss of ≥ 250 ml of blood within 3 months prior to screening.
- Treatment with an investigational drug within 30 days prior to screening.
- Previous treatment with any prescribed or over the counter medications (including herbal medicines such as St John's Wort) within 2 weeks prior to the intended start of study.
- Legal incapacity or limited legal capacity at screening.
- Positive results from urine drug screen at screening.
- History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study drugs, or which might increase the risk for toxicity.
- Known hypersensitivity to any excipients of the drug formulations.
- Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: ACEI-ARB-RI
angiotensin converting enzyme inhibitor (ACEI) angiotensin receptor antagonist (ARB) renin inhibitor (RI)
|
Andre navn:
Andre navn:
Andre navn:
|
|
Eksperimentell: ARB-RI-ACEI
|
Andre navn:
Andre navn:
Andre navn:
|
|
Eksperimentell: RI-ACEI-ARB
|
Andre navn:
Andre navn:
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
RAS-peptide profile
Tidsramme: 0-192h
|
0-192h
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Blood pressure and heart rate
Tidsramme: 0-192 h
|
0-192 h
|
|
Aldosterone concentrations
Tidsramme: 0-192 h
|
0-192 h
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Manuel Haschke, PD Dr. med., Clinical Pharmacology, University Hospital Basel
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- USBMH-001
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .